mdi Consultants, IncLaunching a medical device in the United States begins with one of the most important regulatory decisions you’ll make—determining the correct FDA premarket submission pathway.
Should you submit a 510(k), pursue a De Novo Request, or prepare a Premarket Approval (PMA) application?
The answer depends on your device’s intended use, technological characteristics, risk classification, and whether a legally marketed predicate device already exists. Selecting the wrong pathway can result in months of unnecessary delays, additional testing, higher regulatory costs, and, in some cases, the need to prepare an entirely new submission.
The Short Answer
- Choose a 510(k) if your device is substantially equivalent to a legally marketed predicate device.
- Choose a De Novo Request if your device is novel, presents low to moderate risk, and no suitable predicate exists.
- Choose a PMA if your device is classified as Class III because it supports or sustains human life, is implanted, or presents a significant risk to patients.
While development costs and review timelines are important considerations, FDA determines the appropriate pathway based on the device’s regulatory classification—not the manufacturer’s preference.
FDA Submission Pathways Compared
| Feature | 510(k) | De Novo Request | PMA |
| Typical Device Class | Class II | Class I or Class II | Class II |
| Predicate Device Required | Yes | No | No |
| Intended Use | Devices substantially equivalent to an existing legally marketed device | Novel low- or moderate-risk devices | High-risk devices |
| Primary Review Standard | Substantial Equivalence | Reasonable Assurance of Safety and Effectiveness through General and/or Special Controls | Valid Scientific Evidence Demonstrating Safety and Effectiveness |
| Clinical Data | Sometimes | Sometimes | Usually Required |
| Review Complexity | Moderate | High | Very high |
| Relative FDA Review Time | Fastest | Moderate | Longest |
| Relative Regulatory Cost | Lowest | Moderate | Highest |
What Is a 510(k)?
A 510(k) Premarket Notification is the most common FDA submission pathway for medical devices.
To obtain clearance, the manufacturer must demonstrate that the new device is substantially equivalent to a legally marketed predicate device with respect to:
- Intended use
- Indications for use
- Technological characteristics
- Performance
- Safety
- Effectiveness
For many Class II devices, the 510(k) pathway provides the shortest route to market.
What Is a De Novo Request?
The De Novo pathway was created for innovative devices that do not have a legally marketed predicate, yet present only low or moderate risk.
Instead of demonstrating substantial equivalence, the manufacturer must establish that the risks can be adequately controlled through:
- General controls
- Special controls
- Appropriate performance testing
- Labeling
- Risk management
Once FDA grants a De Novo Request, the device type receives a new classification regulation and product code. Future manufacturers of substantially equivalent devices may often use the 510(k) pathway instead of submitting another De Novo Request.
What Is a PMA?
A Premarket Approval (PMA) application is FDA’s most rigorous review process and is generally required for Class III medical devices.
These devices typically:
- Support or sustain human life
- Are implanted for extended periods
- Prevent significant impairment of human health
- Present a potentially unreasonable risk if they fail
Unlike a 510(k), a PMA requires manufacturers to independently demonstrate that the device is safe and effective using valid scientific evidence.
Because of the volume of information required, PMA applications generally require substantially more time and resources than either a 510(k) or De Novo Request.
How Do You Determine Whether a Predicate Device Exists?
One of the first regulatory activities should be conducting a comprehensive predicate device search.
A suitable predicate should have:
- The same intended use
- Similar indications for use
- Comparable technological characteristics
- Similar performance and safety profile
Finding a device with a similar appearance is not enough. FDA evaluates whether the technological differences raise new questions regarding safety or effectiveness.
If an appropriate predicate cannot be identified, the regulatory strategy may shift toward either a De Novo Request or a PMA, depending on the device’s risk classification.
For this reason, a thorough regulatory assessment early in product development can save months of unnecessary work.
Human Factors and Usability Continue to Receive Increased FDA Attention
Manufacturers should also recognize FDA’s continued emphasis on human factors engineering and usability.
Devices intended for use by healthcare professionals, caregivers, or patients should incorporate usability considerations early in product development. Manufacturers should document user needs, identify critical tasks, evaluate use-related risks, and determine whether human factors validation testing is necessary.
Addressing these expectations early can help reduce the likelihood of receiving additional information requests during FDA review.
Which FDA Pathway Is Right for Your Device?
The following questions provide a useful starting point:
- Is there a legally marketed predicate device?
- What is the device classification?
- Does the technology introduce new questions regarding safety or effectiveness?
- Will FDA likely require clinical evidence?
- Are there recognized consensus standards that apply?
- What testing will be necessary before submission?
- Would a Pre-Submission meeting with FDA reduce regulatory uncertainty?
A comprehensive regulatory strategy developed early in the product lifecycle often reduces costs, shortens review time, and minimizes the risk of avoidable deficiencies.
Why Regulatory Strategy Matters?
Many manufacturers assume they already know which submission pathway applies, only to discover later that FDA disagrees.
Beginning development under the wrong regulatory strategy can lead to:
- Additional testing
- Multiple rounds of FDA questions
- Project delays
- Increased regulatory expenses
- New submission requirements
- Delayed market entry
An experienced regulatory assessment performed before testing begins often prevents these costly setbacks.
Since 1978, mdi Consultants, Inc. has helped medical device manufacturers worldwide navigate the FDA regulatory process. Our regulatory specialists assist companies with:
- Regulatory pathway assessments
- Predicate device searches
- FDA classification determinations
- 510(k) preparation and submission
- De Novo Requests
- PMA applications
- FDA Pre-Submission (Q-Submission) meetings
- Performance testing strategy
- Human factors planning
- Biocompatibility and sterilization reviews
- FDA Establishment Registration and Device Listing
